Granted Patent
B2
US 12,303,537 · App. 18/820,753 · Granted May 20, 2025
Bacteriotherapy for clostridium difficile colitis
Assignee:
Ferring Microbiome Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.
Claims (24)
1. An oral composition, comprising:
a processed fecal sample obtained from a human donor; and
glycerol.
2. The composition of claim 1 , wherein the processed fecal sample has been prepared by a process comprising screening for pathogens.
3. The composition of claim 1 , wherein the processed fecal sample has been prepared by a process comprising filtration.
4. The composition of claim 1 , wherein the composition is comprised in an oral capsule.
5. A method of reducing the risk of a recurrent Clostridium difficile infection, comprising orally administering an oral capsule containing a composition comprising a processed fecal sample obtained from a human donor and glycerol to a subject in need thereof.
6. The method of claim 5 , wherein the processed fecal sample has been screened for pathogens.
7. The method of claim 5 , wherein the patient has been treated with an antibiotic prior to the administration.
8. The method of claim 5 , wherein the subject has or previously has had a C. difficle infection.
9. The method of claim 5 , wherein the subject has previously been treated for C. difficle infection.
10. A fecal microbiota composition, comprising:
a processed fecal sample obtained from a human donor;
and an effective amount of a cryoprotectant.
11. The composition of claim 10 , wherein the cryoprotectant comprises one or more selected from a glycol, glycerol, dimethyl sulfoxide, dairy milk, and soy milk.
12. The composition of claim 10 , wherein the cryoprotectant comprises glycerol.
13. A method of treating a gastrointestinal disorder, comprising administering a composition according to claim 10 to a subject in need thereof.
14. The method of claim 13 , wherein the composition has been processed for nasogastric delivery, and the method comprises administering the composition by nasogastric delivery.
15. The method of claim 13 , wherein the composition has been processed for delivery by enema, and the method comprises administering the composition by enema.
16. The method of claim 13 , wherein the composition has been processed for delivery by colonoscopy, and the method comprises administering the composition by colonoscopy.
17. The method of claim 13 , wherein the composition is comprised in an oral tablet, and the method comprises orally administering the tablet.
18. The method of claim 13 , wherein the composition is comprised in an oral capsule, and the method comprises orally administering the capsule.
19. The method of claim 13 , wherein the subject has or previously has had a C. difficle infection.
20. The method of claim 13 , wherein the subject has previously been treated for C. difficle infection.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2025
From: HLAVKA, EDWIN J.
To: MIKROBEX, INC.
Reel/Frame 070914/0164 →
CHANGE OF NAME
Recorded Apr 22, 2025
From: MIKROBEX INC.
To: REBIOTIX, INC.
Reel/Frame 070946/0535 →
CHANGE OF NAME
Recorded Apr 22, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070947/0158 →
Continuity (10)
Continuation
13576573
Provisional Application
61351184
· Jun 3, 2010
Provisional Application
61337283
· Feb 1, 2010
References Cited (400)
US 3261761A
· Anderson
· 1966
[cited by applicant]
US 3317675A
· Harris et al.
· 1967
[cited by applicant]
US 4636412A
· Field
· 1987
[cited by applicant]
US 5196205A
· Borody
· 1993
[cited by applicant]
US 5229374A
· Burton et al.
· 1993
[cited by applicant]
US 5274001A
· Borody
· 1993
[cited by applicant]
US 5364756A
· Livesey et al.
· 1994
[cited by applicant]
US 5443826A
· Borody
· 1995
[cited by applicant]
US 5476669A
· Borody
· 1995
[cited by applicant]
US 5519014A
· Borody
· 1996
[cited by applicant]
US 5599795A
· McCann et al.
· 1997
[cited by applicant]
US 5711446A
· Jeffs et al.
· 1998
[cited by applicant]
US 5837238A
· Casas et al.
· 1998
[cited by applicant]
US 5858403A
· Borody et al.
· 1999
[cited by applicant]
US 5902578A
· Halpin-Dohnalek et al.
· 1999
[cited by applicant]
US 5925354A
· Fuller et al.
· 1999
[cited by applicant]
US 6096310A
· Bier
· 2000
[cited by applicant]
US 6103268A
· Borody et al.
· 2000
[cited by applicant]
US 6132767A
· Borody et al.
· 2000
[cited by applicant]
US 6214341B1
· Thomas et al.
· 2001
[cited by applicant]
US 6391224B1
· Wowk
· 2002
[cited by applicant]
US 6426338B1
· Borody
· 2002
[cited by applicant]
US 6428783B1
· Khachatrian et al.
· 2002
[cited by applicant]
US 6635260B1
· Gerding
· 2003
[cited by applicant]
US 6645530B1
· Borody
· 2003
[cited by applicant]
US 6680168B2
· Thomas et al.
· 2004
[cited by applicant]
US 6805852B2
· Lin et al.
· 2004
[cited by applicant]
US 6861053B1
· Lin et al.
· 2005
[cited by applicant]
US 6969520B2
· Thomas et al.
· 2005
[cited by applicant]
US 7048906B2
· Lin et al.
· 2006
[cited by applicant]
US 7125708B2
· Wynne et al.
· 2006
[cited by applicant]
US 7307062B2
· Bolte
· 2007
[cited by applicant]
US 7607776B1
· Lewis et al.
· 2009
[cited by applicant]
US 7993682B2
· Borody et al.
· 2011
[cited by applicant]
US 8058418B2
· Boyle et al.
· 2011
[cited by applicant]
US 8110177B2
· Lin et al.
· 2012
[cited by applicant]
US 8460648B2
· Borody
· 2013
[cited by applicant]
US 8722088B2
· Olesen et al.
· 2014
[cited by applicant]
US 8772242B2
· Borody
· 2014
[cited by applicant]
US 8906668B2
· Henn et al.
· 2014
[cited by applicant]
US 9011834B1
· McKenzie et al.
· 2015
[cited by applicant]
US 9433651B2
· Jones et al.
· 2016
[cited by applicant]
US 9463208B2
· Hlavka
· 2016
[cited by applicant]
US 9511099B2
· Jones et al.
· 2016
[cited by applicant]
US 9511100B2
· Jones et al.
· 2016
[cited by applicant]
US 9629881B2
· Hlavka
· 2017
[cited by applicant]
US 9642880B2
· Jones et al.
· 2017
[cited by applicant]
US 9675648B2
· Jones et al.
· 2017
[cited by applicant]
US 9694039B2
· Jones et al.
· 2017
[cited by applicant]
US 9782445B2
· Jones et al.
· 2017
[cited by applicant]
US 20020022019A1
· Laulund
· 2002
[cited by applicant]
US 20020119200A1
· Haskell
· 2002
[cited by applicant]
US 20030031659A1
· Farmer
· 2003
[cited by applicant]
US 20030154105A1
· Ferguson
· 2003
[cited by applicant]
US 20030161871A1
· Hird et al.
· 2003
[cited by applicant]
US 20040062757A1
· Finegold
· 2004
[cited by applicant]
US 20040170617A1
· Finegold
· 2004
[cited by applicant]
US 20040265291A1
· Drake et al.
· 2004
[cited by applicant]
US 20050239706A1
· Backhed et al.
· 2005
[cited by applicant]
US 20060008511A1
· Lin et al.
· 2006
[cited by applicant]
US 20060029608A1
· Thomas et al.
· 2006
[cited by applicant]
US 20060160121A1
· Mounts et al.
· 2006
[cited by applicant]
US 20060210448A1
· Wang et al.
· 2006
[cited by applicant]
US 20070178078A1
· Khoo
· 2007
[cited by applicant]
US 20070212674A1
· Spiers
· 2007
[cited by applicant]
US 20070231336A1
· Thomas et al.
· 2007
[cited by applicant]
US 20080008751A1
· Fox
· 2008
[cited by applicant]
US 20080027353A1
· Kliman
· 2008
[cited by applicant]
US 20080075901A1
· Lee et al.
· 2008
[cited by applicant]
US 20080089870A1
· Ghosh et al.
· 2008
[cited by applicant]
US 20080269258A1
· Breaker et al.
· 2008
[cited by applicant]
US 20090138354A1
· Zech
· 2009
[cited by applicant]
US 20090148540A1
· Martin et al.
· 2009
[cited by applicant]
US 20100008850A1
· Martin
· 2010
[cited by applicant]
US 20100151019A1
· Ramani et al.
· 2010
[cited by applicant]
US 20100172874A1
· Turnbaugh et al.
· 2010
[cited by applicant]
US 20100316617A1
· Renaud et al.
· 2010
[cited by applicant]
US 20110129529A1
· Lin
· 2011
[cited by applicant]
US 20110177976A1
· Gordon et al.
· 2011
[cited by applicant]
US 20110223252A1
· Borody et al.
· 2011
[cited by applicant]
US 20110240511A1
· Bolton et al.
· 2011
[cited by applicant]
US 20120276059A1
· Boone et al.
· 2012
[cited by applicant]
US 20120276060A1
· Boone et al.
· 2012
[cited by applicant]
US 20130022575A1
· Cassity
· 2013
[cited by applicant]
US 20130052172A1
· Baker
· 2013
[cited by applicant]
US 20130064885A1
· Lin et al.
· 2013
[cited by applicant]
US 20130108598A1
· Oresic et al.
· 2013
[cited by applicant]
US 20130149339A1
· Honda et al.
· 2013
[cited by applicant]
US 20130195820A1
· Wacklin et al.
· 2013
[cited by applicant]
US 20140255351A1
· Berstad et al.
· 2014
[cited by applicant]
US 20140363397A1
· Allen-Vercoe et al.
· 2014
[cited by applicant]
US 20140363400A1
· Jones et al.
· 2014
[cited by applicant]
US 20150037285A1
· Blaser et al.
· 2015
[cited by applicant]
US 20150093360A1
· McKenzie et al.
· 2015
[cited by applicant]
US 20160250151A1
· Bochenek et al.
· 2016
[cited by applicant]
US 20160339065A1
· Adams et al.
· 2016
[cited by applicant]
US 20160367607A1
· Hlavka
· 2016
[cited by applicant]
US 20170266241A1
· Hlavka
· 2017
[cited by applicant]
US 20180000872A1
· Hamilton et al.
· 2018
[cited by applicant]
US 20190365831A1
· Jones et al.
· 2019
[cited by applicant]
US 20210283197A1
· Blount et al.
· 2021
[cited by applicant]
US 20230364159A1
· Jones et al.
· 2023
[cited by applicant]
CA 1337265C
· 1995
[cited by applicant]
CN 107921072A
· 2018
[cited by applicant]
CN 107949391A1
· 2018
[cited by applicant]
EP 1300472A1
· 2003
[cited by applicant]
EP 1340078B1
· 2003
[cited by applicant]
EP 1432786B1
· 2004
[cited by applicant]
EP 2636684A1
· 2013
[cited by applicant]
EP 2783688A1
· 2014
[cited by applicant]
JP 2001327280A
· 2001
[cited by applicant]
JP 2015091647A
· 2015
[cited by applicant]
WO WO8903219A1
· 1989
[cited by applicant]
WO WO8905559A1
· 1989
[cited by applicant]
WO WO8905659A1
· 1989
[cited by applicant]
WO WO9001335A1
· 1990
[cited by applicant]
WO WO9206690A1
· 1992
[cited by applicant]
WO WO9611014A1
· 1996
[cited by applicant]
WO WO9641615A2
· 1996
[cited by applicant]
WO WO9709886A1
· 1997
[cited by applicant]
WO WO9850043A1
· 1998
[cited by applicant]
WO WO0193904A1
· 2001
[cited by applicant]
WO WO0197821A1
· 2001
[cited by applicant]
WO WO0207741A1
· 2002
[cited by applicant]
WO WO03002713A2
· 2003
[cited by applicant]
WO WO03074061A1
· 2003
[cited by applicant]
WO WO2007018563A2
· 2007
[cited by applicant]
WO WO2008076696A2
· 2008
[cited by applicant]
WO WO2009055362A1
· 2009
[cited by applicant]
WO WO2009120347A2
· 2009
[cited by applicant]
WO WO2010002890A2
· 2010
[cited by applicant]
WO WO2010019208A1
· 2010
[cited by applicant]
WO WO2011033310A1
· 2011
[cited by applicant]
WO WO2011036539A1
· 2011
[cited by applicant]
WO WO2011047439A1
· 2011
[cited by applicant]
WO WO2011050397A1
· 2011
[cited by applicant]
WO WO2011094027A1
· 2011
[cited by applicant]
WO WO2011107481A2
· 2011
[cited by applicant]
WO WO2011107482A2
· 2011
[cited by applicant]
WO WO2012013861A2
· 2012
[cited by applicant]
WO WO2012016287A2
· 2012
[cited by applicant]
WO WO2012024638A2
· 2012
[cited by applicant]
WO WO2012033814A2
· 2012
[cited by applicant]
WO WO2012050513A1
· 2012
[cited by applicant]
WO WO2012118535A1
· 2012
[cited by applicant]
WO WO2012122478A1
· 2012
[cited by applicant]
WO WO2012142605A1
· 2012
[cited by applicant]
WO WO2012149351A1
· 2012
[cited by applicant]
WO WO2012159023A2
· 2012
[cited by applicant]
WO WO2013053836A1
· 2013
[cited by applicant]
WO WO2013090825A1
· 2013
[cited by applicant]
WO WO2013130773A2
· 2013
[cited by applicant]
WO WO2013150331A1
· 2013
[cited by applicant]
WO WO2013163582A1
· 2013
[cited by applicant]
WO WO2013171515A1
· 2013
[cited by applicant]
WO WO2014006532A1
· 2014
[cited by applicant]
WO WO2014078911A1
· 2014
[cited by applicant]
WO WO2014082050A1
· 2014
[cited by applicant]
WO WO2014082132A1
· 2014
[cited by applicant]
WO WO2014121298A3
· 2014
[cited by applicant]
WO WO2014121301A1
· 2014
[cited by applicant]
WO WO2014121302A2
· 2014
[cited by applicant]
WO WO2014121304A1
· 2014
[cited by applicant]
WO WO2014145958A2
· 2014
[cited by applicant]
WO WO2014152484A1
· 2014
[cited by applicant]
WO WO2014153194A2
· 2014
[cited by applicant]
WO WO2014197562A1
· 2014
[cited by applicant]
WO WO2015026235A2
· 2015
[cited by applicant]
WO WO2016201114A1
· 2016
[cited by applicant]
WO WO2017118924A1
· 2017
[cited by applicant]
“Laboratory Blender Stomach action—BagSystem?”, Topac BagSystem Datasheet, pp. 1-2, 1998.
[cited by applicant]
“Pharmacy”, edited by Chang Xingsheng, China Light Industry Press, 1st version, pp. 316-317, section VI, publication date: Apr. 30, 2004.
[cited by applicant]
510(k) Summary (K101003) Submitted by Vitrolife Sweden AB for RapidVit Blast and RapidWarm Blast (Dec. 10, 2010).
[cited by applicant]
510(k) Summary (K991421) Submitted by Irvine Scientific Sales Co., Inc. for Freezing Medium TEST Yolk Buffer (TYB) with Glycerol and Refrigeration Medium TEST Yolk Buffer (TYB) (Apr. 20, 1999).
[cited by applicant]
A. Gustafsson, S. Lund-Tonnesen, A. Berstad, T. Midtvedt, E. Norin (1998), “Faecal Short-Chain Fatty Acids in Patients with Antibiotic-Associated Diarrhoea, before and after Faecal Enema Treatment”, Scandinavian Journal…
[cited by applicant]
Aas et al., “Recurrent Clostridium difficile Colitis: Case Series Involving 18 Patients Treated with Donor Stool Administered via a Nasogastric Tube,” Clin Infect Dis, vol. 36, (Mar. 2003), pp. 580-585.
[cited by applicant]
Aas, J et al, C Diff Treatment with Fecal Transplant, Stool transplantation for older patients with clostridium difficile infection, 2009.
[cited by applicant]
Abbeele et al., “Microbial Community Development in a Dynamic Gut Model Is Reproducible, Colon Region Specific, and Selective for Bacteroidetes and Clostridium Cluster IX,” Applied and Environmental Microbiology, vol. 7…
[cited by applicant]
Abubaker, I et al, Microbiome papers, Health Technology Assesmenl 2007 vol. 11 No. 36, 2007.
[cited by applicant]
Acha, S.J. et al, Microbe preservation, Changes of viability and composition of the
[cited by applicant]
Adams, Stephen, et al, Ulcerative Colitis, Ulcerative Colitis, 2013.
[cited by applicant]
Adler, A., et al., “Trends and Changes in Clostridium difficile Diagnostic Profiles and Their Impact on the Proportion of Positive Samples: a National Survey”, Clin. Microbiol Infect. Mar. 27, 2014, 10.1111/1469-0691.12…
[cited by applicant]
Agar Plate Info, BBL Bacteroides Bile Esculin Agar {BBE), 2006.
[cited by applicant]
Alexander Khoruts et al. “Understanding the mechanisms of faecal microbiota transplantation” Nat Rev Gastroenterol Hepatol. Sep. 2016 ; 13(9); pp. 508-516.
[cited by applicant]
Ali, Shanom, Healthcare industry, Diverse sources of C. difficile infection, 2014.
[cited by applicant]
Allen, Stephen et al., Drug Delivery, Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhea and clostridium difficile diarrhea in older inpatients {PLACIDE): a randomized, double-blind, pla…
[cited by applicant]
Allen-Vercoe, Emma et al, C Diff Treatment with Fecal Transplant, A canadian working group report on fecal microbial therapy: microbial ecosystems therapeutics, 2012.
[cited by applicant]
Alonso, Carolyn; Marr, Kieren, C Diff Studies, Colostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis, 2013.
[cited by applicant]
Alsharif, R., et al., Counting Bacteria, Bacterial detection and live/dead discrimination by flow cytometry, 2002.
[cited by applicant]
Amann, RI et al., Counting Bacteria, Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations, 1990.
[cited by applicant]
Ananthakrishnan, A. et al, GI Disease—General, Genetic risk factors for Colostridium difficile infection in ulcerative colitis, 2013.
[cited by applicant]
Andoh, A. et al, Chrohn's Disease, Multicenter analysis of fecal microbiota profiles in Japanese patients with Chron's disease, 2012.
[cited by applicant]
Angelberger, S. et al, Ulcerative Colitis, Temporal bacterial community dynamics vary among uncerative colitis patients after fecal microbiota transplantation, 2013.
[cited by applicant]
Anonymous, “Polyethylene Glycol (PEG) Selection Guide”, SIGMA, Mar. 10, 2020, URL: https://www.sigmaaldrich.com/NL/en/technical-documents/technical-article/materials-science-and-engineering/drug-delivery/polyethylene-gl…
[cited by applicant]
Ariefdjohan et al., “Comparison of DNA extraction kits for PCR-DGGE analysis of human intestinal microbial communities from fecal specimens,” Nutrition Journal, vol. 9 No. 23, pp. 1-8 (May 2010).
[cited by applicant]
Arkkila, P. E., C Diff Treatment with Fecal Transplant, Fecal bacteriotherapy for recurrent clostridium difficile infection, 2011.
[cited by applicant]
Aronoff, D.M., “Host-Pathogen Interactions in Clostridium difficile Infection: It Takes Two to Tango”, Clin Infect Dis. (2014) 58 (10):1401-1403.
[cited by applicant]
Arthur, J.; Jobin, C., Cancer, “The struggle within: microbial influences on colorectal cancer”, Inflamm Bowel Dis. Jan. 2011 ; 17(1): 396-409.
[cited by applicant]
Arthur, J.; Jobin, C., Cancer, The struggle within: microbial influences on colorectal cancer, 2011.
[cited by applicant]
Arumugam, M. et al., Analysis of Species in Feces, Enterotypes of the human gut microbiome, 2011.
[cited by applicant]
Arvand, M., et al., “Increased incidence of Clostridium difficile PCR ribotype 027 in Hesse, Germany, 2011 to 2013”, Euro Surveill, 2014: 19(10) 1-6.
[cited by applicant]
Aslam, S et al, C Diff Studies, Treatment of clostridium difficile-associated disease: old therapies and new strategies, 2005.
[cited by applicant]
Aspevall, 0., et al., “Performance of Four Chromogenic Urine Culture Media after One or Two Days of Incubation Compared with Reference Media”, Journal of Clinical Microbiology, vol. 40, No. 4, Apr. 2002, 1500-1503.
[cited by applicant]
ASTM International, “Standard Practice for Climatic Stressing of Packaging Systems for Single Parcel Delivery”, Book of Standards vol. 15.10, 2010, 10.1520/F2825-10E01 (3 pgs.).
[cited by applicant]
Atarashi, K. et al, Analysis of Species in Feces, Treg introduction by a rationally selected mixture of colostrudia strains from the human microbiota, 2013.
[cited by applicant]
Aye et al., “Assessment of the Genotoxicity of three cryoprotectants used for human oocyte vitrification: Dimethyl sulfoxide, ethylene glycol and propylene glycol,” Food and Chemical Toxicology, vol. 48, pp. 1905-1912 (…
[cited by applicant]
Azad, M. et al., Pediatrics, Gut microbiota of healthy canadian infants: profiles by mode of delivery and infant diet at 4 months, 2013.
[cited by applicant]
Backhed, Fredrik et al, Gut Microbiome News, Host-Bacterial mutualism in the human intestine, 2005.
[cited by applicant]
Baheti et al., “Excipients used in lyophilization of small molecules,” J. Excipients and Food Chem. vol. 1 No. 1, (2010).
[cited by applicant]
Bakken, J., et al., “Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection”, Anaerobe, vol. 15, Sep. 2009, pp. 285-289, Elsevier Ltd.
[cited by applicant]
Bakken, J., et al., “Treating Clostridium difficile Infection With Fecal Microbiota Transplantation”, Clinical Gastroenterology and Hepatology 2011;9: 1044-1049.
[cited by applicant]
Bakken, Johan et al, C Diff Studies, Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection {RCDI) among infectious disease physicians, 2013.
[cited by applicant]
Bakken, Johan et al, C Diff Treatment with Fecal Transplant, Treating clostridium difficile infection with fecalmicrobiota transplantation, 2011.
[cited by applicant]
Barbut, F., et al., “Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management?”, Clinical Microbiology and Infection, vol. 20, No. 2, Feb. 2014, 136-144.
[cited by applicant]
Barletta, J. et al., Intestinal pH, Proton pump inhibitors and the risk for hospital aquired colostridium difficile infection, 2013.
[cited by applicant]
Baron, Todd, C Diff Treatment with Fecal Transplant, Fecal Microbiota Transplant: We know its history, but can we predict its future?, 2013.
[cited by applicant]
Barr, David, Industry, CGMPs in the production of clinical supplies, 2007.
[cited by applicant]
Bartlett, J., “A Call to Arms: The Imperative for Antimicrobial Stewardship”, CID, 2011 :53 (Suppl 1) S4-S7.
[cited by applicant]
Bauer, et al, C Diff Studies, Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile 2013.
[cited by applicant]
BD, Agar Plate Info, Brucella Blood Agar with Hemin and Vitamin K1, 2011.
[cited by applicant]
Bell, Caitlin H, Centrifugation, The Effects of Centrifugation and Filtration as Pre-Treatments in Bacterial Retention Studies, 2005.
[cited by applicant]
Ben-Amor, Kaouther et al, Analysis of Species in Feces, Genetic diversity of viable, injured and dead fecal bacteria assessed by fluorecence-activated cell sorting and 16S rRNA gene analysis, 2005.
[cited by applicant]
Ben-Amor, Kaouther et al, Counting Bacteria, Multiparametric flow cytometry and cell sorting for the assessment of viable, injured, and dead bifidobacterium cells during bile salt stress, 2002.
[cited by applicant]
Benjamin, et al, Chrohn's Disease, Smokers with Active Crohn's Disease Have a Clinically Relevant Dysbiosis of the Gastrointestinal Microbiota, 2011.
[cited by applicant]
Bennet, Justin et al, C Diff Treatment with Fecal Transplant, Treatment of ulcerative colitis by implantation of normal colonic flora, 1989.
[cited by applicant]
Bennett, P.S., et al., What Nurses Need to Know About Fecal Microbiota Transplantation: Education, Assessment, and Care for Children and Young Adults, J_ Pediatr Nurs., Feb. 7, 2014, doi: 10.1016/j. pedn.2014.01 .013 (8…
[cited by applicant]
Berejnov, V. et al, Cryopreservation Studies, Effects of cryoprotectant concentration and cooling rate on vitrification of aqueous solutions, 2006.
[cited by applicant]
Berejnov, V., et al., “Effects of cryoprotectant concentration and cooling rate on vitrification of aqueous solutions,” J. Appl. Cryst. (2006) 39, 244-251.
[cited by applicant]
Bervoets, L. et al, Pediatrics/Obesity Related, Differences in gut microbiota composition between obese and lean children: a cross-sectional study, 2013.
[cited by applicant]
Best, E. et al, Industry, The Potential for Airborne Dispersal of Clostridium difficile from Symptomatic Patients, 2012.
[cited by applicant]
Bhat, A. et al, Cryopreservation Studies, Bacillus subtilis natto: a non-toxic source of poly-y-glutamic acid that could be used as a cryoprotectant for probiotic bacteria, 2013.
[cited by applicant]
Bodger, K. et al, Industry, Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire, 2013.
[cited by applicant]
Boenning, D.A., et al., “Clostridium difficile in a pediatric outpatient population”, Pediatric Infectious Disease, vol. 1, No. 5, 336-338.
[cited by applicant]
Bonavia et al., “Bacteria Cryopreservation Protocol: Protocol Exchange,” 5 pages (2012) Available online, URL: http://www.nature.com/protocolexchange/protocols/2326.
[cited by applicant]
Bonfrate, Leoni Ide et al., GI Disease—General, Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options, 2013.
[cited by applicant]
Boone, J.H., et al., “Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency”, Eur J Clin Microbiol Infect Dis (2012) 31:155…
[cited by applicant]
Borody et al., “Clostridium Difficile Complicating Inflammatory Bowel Disease: Cure after Fecal Bacteriotherapy,” FMT Studies and Reviews, pp. 1-1, 2008.
[cited by applicant]
Borody et al., “Bacteriotherapy Using Fecal Flora: Toying with Human Motions” J. Clin. Gastroenterol., vol. 38 No. 6, pp. 475-483 (Jul. 2004).
[cited by applicant]
Borody et al., “Faecal bacteriotherapy (FB) for chronic C. difficile (Cd) syndromes,” Journal of Gastroenterology and Hepatology 18 (Suppl.) (2003).
[cited by applicant]
Borody, T J et al, Bowel disease treatment with FT, Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?, Med. J. Australia 1989.
[cited by applicant]
Borody, T J et al, Bowel disease treatment with FT, Treatment of ulcerative colitis using fecal bacteriotherapy, 2003.
[cited by applicant]
Borody, T J et al; C Diff Treatment with Fecal Transplant, :Fecal microbiota transplantation: Indications, methods, evidence, and future directions Curr Gastroenterol Rep (2013) 15:337.
[cited by applicant]
Borody, T J et al; FMT Studies and Reviews, “Therapeutic faecal microbiota transplantation: current status and future developments” Jan. 2014; 30(1): 97-105.
[cited by applicant]
Borody, T. et al., Fecal bacteriotherapy in the treatment of recurrent C. difficile infection, UpToDate (Aug. 3, 2006).
[cited by applicant]
Borody, T.J., et al., “Bacteriotherapy Using Fecal Flora”, J Clin Gastroenterol, vol. 38, No. 6, Jul. 2004, pp. 475-183, Lippincott Williams & Wilkins.
[cited by applicant]
Borody, Thomas J; et al; “Bacteriotherapy Using Fecal Flora: Toying With Human Motions” Journal of Clinical Gastroenterology,. 38, 475-483, 2004 (Year: 2004).
[cited by applicant]
Bowden, Talmadge et al, Bowel disease treatment with FT, Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis, 1981.
[cited by applicant]
Brace, C., et al., “Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations”, J Crohns Colitis (2014), http://dx.doi.or…
[cited by applicant]
Brahe, L.K. and Larson, L.H., Obesity Related, Is butyrate the link between diet, intestinal microbiota and obesity related metabolic diseases?, 2013.
[cited by applicant]
Brandt, Lawrence, C-Diff Treatment with Fecal Transplant, Norovirus Gastroenteritis After Fecal Microbiota Transplantation for Treatment of Colostridium Difficile Infection Despite Asymptonatic Donors and Lack of Sick C…
[cited by applicant]
Brandt, Lawrence; Aroniadis, Olga, C Diff Treatment with Fecal Transplant, An overview of fecal microbiota transplantation: techniques, indications and outcomes, 2013.
[cited by applicant]
Brandt, Let al, C Diff Treatment with Fecal Transplant, American journal of gastroenterology lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of c diff infection, 2012.
[cited by applicant]
Brandt, Let al, C Diff Treatment with Fecal Transplant, Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent clostridium difficile infection (paper and question/answer with Brandt), 2012.
[cited by applicant]
Brecher, S. et al, C Diff Studies, Laboratory diagnosis of colostridium difficile infections: a practical guide for clinicians: there is a light at the end of the colon, 2013.
[cited by applicant]
Britton, R., et al., Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficle, Gastroenterology (2014) (19 pgs.).
[cited by applicant]
Brown, J. et al, Microbiome papers, Translating the human microbiome, 2013.
[cited by applicant]
Buffie, C.; Palmer, E., Microbiome papers, Microbiota-mediated colonization resistance against intestinal pathogens, 2013.
[cited by applicant]
Burke, Kristin et al, C Diff Treatment with Fecal Transplant, Fecal Transplantation for recurrent colostridium difficile infection in older adults: a review, 2013.
[cited by applicant]
Burnham, Carey-Ann; Carroll, Karen, C Diff studies, Diagnosis of colostridium difficile infection: an ongoing conundrum for clinicians and clinical laboratories, 2013.
[cited by applicant]
C. Guerin-Danan, “Storage of intestinal bacteria in samples frozen with glycerol,” Microbial Ecology in Health and Disease, vol. 11, No. 3, Jan. 1, 1999, pp. 180-182.
[cited by applicant]
Cabotaje, L. et al., Neutral Sugar Composition and Gravimetric Yield of Plant and Bacterial Fractions of Feces, Applied & Envtl. Microbiol. 56: 1786-1792 (1990).
[cited by applicant]
Calabrese, R. et al, Industry, Finding common ground with ISO 9001 and FDA Good Manufacturing Practices, 2013.
[cited by applicant]
Cammarota, G. et al, FMT Studies and Reviews, Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection A Systematic Review, 2014.
[cited by applicant]
Cammarota, G. et al., FMT Studies and Reviews, Fecal transplantation for Colostridium difficile infection. Three cases treated in italy, 1993.
[cited by applicant]
Cardona, S. et al., Microbe preservation, Storage conditions of intestinal microbiota matter in metagenomic analysis, 2012.
[cited by applicant]
Carroll, I et al, Analysis of Species in Feces, Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage, 2012.
[cited by applicant]
CDC, “Vital Signs: Preventing Clostridium difficile Infections”, MMWR, Mar. 9, 2012, vol. 61, No. 9, 157-162.
[cited by applicant]
CDC, Industry, Antibiotic resistance threats in the United States, 2013, 2013.
[cited by applicant]
Chandel, N; Budlinger, G.R., Industry, The good and bad of antibiotics, 2013.
[cited by applicant]
Chang, Ju Young et al, Analysis of Species in Feces, Decreased diversity of the fecal microbiome in recurrent clostridium difficile-associated diarrhea, 2008.
[cited by applicant]
Chassard, C. et al, GI Disease—General, Functional dysbiosis within the gut microbiota of patients with constipated irritable bowel syndrome, 2011.
[cited by applicant]
Chavarri, Maria et al, Drug Delivery, Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions, 2010.
[cited by applicant]
Chen et al., “Fecal detection of enterotoxigenic Bacteroides fragilis”, European Journal of Clinical Microbiology & Infectious Diseases., Springer, Wiesbaden, vol. 34, No. 9, pp. 1871-1877 (Sep. 2013).
[cited by applicant]
Chilton, C.H., et al., “Successful treatment of simulated Clostridum difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure”, J Antimicrob Chemother 2014; 69:451…
[cited by applicant]
Chisti, Y., “Hydrodynamic Damage to Animal Cells”, Critical Reviews in Biotechnology, 21(2):67-110 (2001).
[cited by applicant]
Chitnis, A. et al, C Diff Studies, Epidemiology of community-associated colostridium difficile infection, 2009 through 2011, 2013.
[cited by applicant]
Claaa, E. et al, Analysis of Species in Feces, Performance of the xTAGR Gastrointestinal Pathogen Panel, a Multiplex Molecular Assay for Simultaneous Detection of Bacterial, Viral, and Parasitic Causes of Infectious Gas…
[cited by applicant]
Clabots, C. et al, Strain typing, Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems., 1993.
[cited by applicant]
Clarke, S. et al, Microbiome papers, The gut microbiota and it's relationship to diet and obesity, 2012.
[cited by applicant]
Cleland et al. J. Microbiol. Meth., 58:31-38 (2004) (Abstract).
[cited by applicant]
Clemente, J. et al, Microbiome papers, The Impact of the Gut Microbiota on Human Health: An Integrative View, 2012.
[cited by applicant]
Cnops, L.; Van Esbroeck, M., Bacterial Preservation via Freezing, Freezing of stool samples improves real-time PCR delection of Entamoeba dispar and Entamoeba histolytica, 2010.
[cited by applicant]
Cody, W. et al., “Skim Milk Enhances the Preservation of Thawed -80 Degrees C. Bacterial Stocks”, J Microbiol Methods 75: 135-138 (Sep. 2008).
[cited by applicant]
Cody, William et al, Cryopreservation Studies, Skim milk enhances the preservation of thawed—BOC bacterial stocks, 2008.
[cited by applicant]
Cohen, S.H., et al., “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (…
[cited by applicant]
Collins, Donald, Bowel disease treatment with FT, Pseudomembranous entercolitis—further observations on the value of donor fecal enemata as an adjunct in the treatment of pseudomembranous entercolitis, 1960.
[cited by applicant]
Collins, S. et al, Microbiome papers, The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications, 2013.
[cited by applicant]
Comito, D.; Romano, C., Pediatrics, Dysbiosis in the Pathogenesis of Pediatric Inflammatory Bowel Diseases, 2012.
[cited by applicant]
Communication pursuant to Article 94(3) EPC received in European Patent Application No. 22160187.5 dated Apr. 24, 2024.
[cited by applicant]
Coteur, G., et al., “Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease”, Aliment Pharmacol Ther 29, (2009)…
[cited by applicant]
Cotta, Michael et al., Analysis of Species in Feces, Isolation, characterization and comparison of bacteria from swine faeces and manure storage pits, 2003.
[cited by applicant]
Counting Bacteria, Live/Dead Baclight bacterial viability kits, 2008.
[cited by applicant]
Cox, C.S., “Bacterial Survival in Suspension in Polyethylene Glycol Solutions,” J. Gen. Microbiol. 45, 275-281 (1966).
[cited by applicant]
Cox, L.; Blaser, M., Obesity Related, Pathways in Microbe-Induced Obesity, 2013.
[cited by applicant]
Coyne et al., J. Bacterial., 190(2):736-742 (2008).
[cited by applicant]
Crook, D. et al., C Diff Studies, Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-Analysis of pivotal randomized controlled trials, 2012.
[cited by applicant]
Curtin, Ciara, Analysis of Species in Feces, Researchers examine the genetic diversity of the human gutrnicrobiome, 2012.
[cited by applicant]
D'Agostino, R.B., et al., “Risk Estimation for Recurrent Clostridium Difficile Infection Based on Clinical Factors”, Clin. Infect Dis May 2014; 58(10):1386-93.
[cited by applicant]
Dallas, K.B., et al., “Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study”, The American Journal of Surgery (2014) 207, 533-539.
[cited by applicant]
Damman, C. et al., FMT Studies and Reviews, The Microbiome and Inflammatory Bowel Disease: Is There aTherapeutic Role for Fecal Microbiota Transplantation?, 2012.
[cited by applicant]
Dan, M et al., Fecal Preservation, Comparison of preservation media and freezing conditions for storage of specimens of faeces, 1989.
[cited by applicant]
David, L. et al, Microbiome papers, Diet rapidly and reproducibly alters the human gut microbiome, 2013.
[cited by applicant]
Davidovics, Z.; Sylvester, F., Ulceratice Colitis, Medical Stool: The Future Treatment for Inflammatory Bowel Disease?, 2013.
[cited by applicant]
De Cruz, P. et al, Analysis of Species in Feces, Characterization of the Gastrointestinal Microbiota in Health and Inflammatory Bowel Disease, 2012.
[cited by applicant]
De Goffau, M. et al., Pediatrics, Fecal Microbiota Composition Differs Between Children With ˜—Cell Autoimmunity and Those Without, 2013.
[cited by applicant]
De Leon et al, Ulcerative Colitis, Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection, 2013.
[cited by applicant]
De Vrieze, Jop, FMT Studies and Reviews, The Promise of Poop, 2013.
[cited by applicant]
Debast, S.; Bauer, M., Industry, European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection {CDI), 2013.
[cited by applicant]
Deshpande, A. et al, Industry, Diagnostic Testing for Clostridium difficile Infection in Patients With Inflammatory Bowel Disease, 2013.
[cited by applicant]
Dethlefsen, L; Reiman, D., Microbiome papers, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, 2010.
[cited by applicant]
Deweerdt, S., “A complicated relationship status”, Nature, Apr. 1, 20147; 508(7496):S61-3.
[cited by applicant]
Dey, Neelendu et al., GI—General, Association of gut microbiota with post-operative clinical course in Crohn's disease, 2013.
[cited by applicant]
Ding, T., et al., “Dynamics and associations of microbial community types across the human body”, Nature, May 1, 20145; 509(7500):357-60.
[cited by applicant]
Dixon, E. et al, Counting Bacteria, Solid-phase microextraction and the human fecal VOC metabolome, 2011.
[cited by applicant]
Dominguez, S.R., et al., “High Colonization Rate and Prolonged Shedding of Clostridium difficile in Pediatric Oncology Patients”, Clin Infect Dis, Apr. 29, 2014 (11 pgs.).
[cited by applicant]
Dominguez-Bello et al., “Do you have a probiotic in your future?,” Microbes and Infection, vol. 10, pp. 1072-1076 (2008).
[cited by applicant]
Downing, N. et al., Healthcare industry, Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012, 2014.
[cited by applicant]
Du Boc, H. et al, GI Disease—General, Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in Inflammatory bowel diseases, 2013.
[cited by applicant]
Du Boc, H. et al, GI Disease—General, Increase in fecal primary bile acids and dysbiosis in patients with diarrhea predominant irritable bowel syndrome, 2012.
[cited by applicant]
Dubberke, ER et al, C Diff Studies, The ecology and pathobiology of clostridium difficile infections: anInterdisciplinary challenge, 2001.
[cited by applicant]
Duleba, K., et al., “Clostridium difficile infection in children hospitalized due to diarrhea”, Eur. J_ Clin. Microbiol. Infect. Dis. (2014) 33:201-209.
[cited by applicant]
Dupont, H, Healthcare industry, Diagnosis and management of colostridium difficile infection, 2014.
[cited by applicant]
Dupont, H.L., “Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets”, Aliment Pharmacol Ther, May 2014; 39(10):1033-42.
[cited by applicant]
Durban et al., “Assessing Gut Microbial Diversity from Feces and Rectal Mucosa,” Microb Ecol., vol. 61, pp. 123-133 (2011).
[cited by applicant]
Durban, Ana et al, GI Disease—General, Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome, 2013.
[cited by applicant]
Durban, Ana et al, GI Disease—General, Structural alterations of faecal and mucosa-associated bacterialcommunities in irritable bowel syndrome, 2012.
[cited by applicant]
Dutta, S.K. et al, FMT Studies and Reviews, Efficacy of Combined Jejunal and Colonic Fecal MicrobiotaTransplantation for Recurrent Clostridium difficile Infection, 2013.
[cited by applicant]
Eckburg, Paul B. et al, Analysis of Species in Feces, Diversity of the Human Intestinal Microbial Flora, 2005.
[cited by applicant]
Ehlermann, P., et al., “Donor fecal transfer for recurrent Clostridium difficile-associated diarrhea in heart transplantation”, The Journal of Heart and Lung Transplantation, vol. 33, No. 5, May 2014, 551-553.
[cited by applicant]
Eiseman, B et al, Bowel disease treatment with FT, Fecal Enema as an adjuct in the treatment ofpseudomembranous enterocolitis, 1958.
[cited by applicant]
El Feghal Y, R.E., et al., “Markers of Intestinal Inflammation, Nol Bacerial Burden, Correlate With Clinical Outcomes in Clostridium difficile Infection”, Clin Infect Dis. Jun. 2013; 56(12):1713-21.
[cited by applicant]
El-Matary, Wael, Donor Screening, Fecal Microbiots Transplantation: Long-Term Safety Issues, 2013.
[cited by applicant]
Elixhauser, A., et al., “Readmissions following Hospitalizations with Clostridium difficile Infections, 2009”, HCUP Statistical Brief #145, Dec. 2012, Agency for Healthcare Research and Quality, Rockville, MD, pp. 1-11.
[cited by applicant]
Elliott, P.; Peakman, T., Industry, The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine, 2008.
[cited by applicant]
Emiliani et al., “Comparison of ethylene glycol, 1,2-propanediol and glycerol for cryopreservation of slow-cooled mouse zygotes, 4-cell embryos and blastocysts, Human Reproduction,” vol. 15, Issue 4, Apr. 2000, pp. 905-…
[cited by applicant]
Examination Report dated Aug. 16, 2023 received in Chinese Patent Application No. 202111357079.X.
[cited by applicant]
Examination Report dated May 1, 2024 received in Canadian Patent Application No. 2,928,652.
[cited by applicant]